Clinical Trials Logo
  1. Home
  2. Other Cancer
  3. NCT03674047

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Other Cancer Clinical Trial

Official title:
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Clinical Trial Summary

This research study is studying a drug as a possible treatment for Bronchiolitis Obliterans Syndrome (BOS) after having an Allogeneic Hematopoietic Cell Transplantation (HCT).

Clinical Trial Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved ruxolitinib for this specific disease but it has been approved for other uses. In this study the investigators are assessing the safety and effectiveness of ruxolitinib when given to participants who have been diagnosed with BOS after HCT. BOS is a sign/symptom of chronic Graft-vs-Host Disease (GVHD), a condition in which cells from the donor's tissue attack the organs after HCT occurs. Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. The investigators believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03674047
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date April 19, 2019
Completion date July 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04340024 - Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Active, not recruiting NCT03609177 - Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly N/A
Active, not recruiting NCT04591431 - The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Phase 2
Recruiting NCT06103669 - Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) N/A
Recruiting NCT04585750 - The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) Phase 1/Phase 2
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Completed NCT03736746 - Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals N/A
Not yet recruiting NCT06397651 - A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live 1:1 Exercise Coaching and Personalised Digital Application on Cancer Survivors' Cost of Care N/A
Completed NCT03638453 - Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention N/A
Active, not recruiting NCT03850912 - Symptom Management Implementation of Patient Reported Outcomes in Oncology N/A
Completed NCT03392090 - SHARE (Sharing Goals and Preferences) Study N/A
Completed NCT03244826 - Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation N/A
Recruiting NCT03517332 - Circulating Tumor DNA Exposure in Peripheral Blood
Completed NCT03721926 - A Geriatric Oncology Collaborative Care Intervention for Older Adults With Advanced Cancer N/A
Active, not recruiting NCT03967379 - Multimodal Mobile Intervention Application (App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors N/A
Completed NCT05176860 - Evaluation of Novel Cone-Beam CT for Guidance and Adaptation of Precision Radiotherapy N/A
Active, not recruiting NCT03752268 - Development of an Intervention to Enhance Cancer Pain Management N/A